Antiplatelet and anticoagulant therapy to prevent bypass graft thrombosis in patients with lower extremity arterial occlusive disease

International Angiology

Volumn 20, Issue 1, 2001, Pages 90-98

  Adam, D J ^a   Stonebridge, P A ^a   Belch, J J F ^a   Murie, J A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Anticoagulants therapeutic use; Arterial occlusive diseases; Bypass grafts; Peripheral vascular diseases; Platelet aggregation inhibitors therapeutic use; Thrombosis prevention and control; Vascular surgical procedures

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BIOMATERIAL; DIPYRIDAMOLE; LOW MOLECULAR WEIGHT HEPARIN; PENTOXIFYLLINE; PLACEBO; POLITEF; SULFINPYRAZONE; TICLOPIDINE; WARFARIN;

ATHEROSCLEROSIS; BYPASS SURGERY; CONTROLLED STUDY; ECONOMIC ASPECT; ERROR; EVIDENCE BASED MEDICINE; FEMOROPOPLITEAL BYPASS; GRAFT FAILURE; GRAFT PATENCY; HUMAN; INCIDENCE; LEG ARTERY; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; OUTCOMES RESEARCH; PATIENT SELECTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTOPERATIVE PERIOD; REVIEW; STENOSIS; SURGICAL TECHNIQUE; THROMBOSIS; VASCULAR SURGERY; VEIN GRAFT;

ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; CONSTRICTION, PATHOLOGIC; DISEASE PROGRESSION; FEMORAL ARTERY; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; POPLITEAL ARTERY; POSTOPERATIVE COMPLICATIONS; THROMBOSIS;

EID: 0034949113     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Graft occlusion
2. Graft stenosis: Justification for 1-year surveillance
3. Clinical, haemodynamic, rheological and biochemical findings in 126 patients with intermittent claudication
4. Prognostic significance of rheological and biochemical findings in patients with intermittent claudication
5. Fibrinogen, factor VIII related antigen, Antithrombin III and A-2 Antiplasmin in peripheral arterial disease
6. Fibrinolytic response to venous occlusion in diabetics with and without micro-angiopathy compared to normal age and sex matched controls
7. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants
8. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease
9. The severity of atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin
10. Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease
11. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment
12. Neutrophil count and amputation in critical limb ischaemia
13. Platelet aggregation in patients with peripheral vascular disease
14. Does 111 indium-platelet deposition predict patency in prosthetic arterial grafts
15. Platelet aggregometry can accurately predict failure of externally supported knitted Dacron femoropopliteal bypass grafts
16. Surgical pharmacotherapy
17. What is the role of oral anticoagulants and platelet inhibitors In peripheral vascular surgery?
18. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: A prospective, randomised study
19. The effects of aspirin, dipyridamole and warfarin in femorodistal reconstruction: Long-term results
20. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery
21. The effects of long-term treatment with oral anticoagulants in patients with peripheral vascular disease
22. The role of oral anticoagulation
23. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis
24. Influence of anticoagulant treatment in preventing graft occlusion following saphenous vein bypass for femoropopliteal occlusive disease
25. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery
26. A double-blind trial to assess long term oral anticoagulant therapy in elderly patients after myocardial infarction
27. The effect of warfarin on mortality and reinfarction after myocardial infarction
28. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction
29. Ticlopidine versus aspirin and dipyridamole: Influence on platelet deposition and three-month patency of polytetrafluoroethylene grafts
30. Effect of the cyclo-oxygenase inhibitor indobufen on platelet accumulation in prosthetic vascular grafts
31. Prevention of platelet aggregation and adherence to prosthetic vascular grafts by aspirin and dipyridamole
32. Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts
33. Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal bypass grafts in man
34. Antithrombotic therapy for vascular prosthesis: An experimental model testing platelet inhibitory drugs
35. Effect of ticlopidine on blood loss, platelet turnover and platelet deposition on prosthetic surfaces in patients undergoing aorto-femoral bypass grafts
36. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency
37. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts
38. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts
39. Prevention of early reocclusion by dipyridamole and aspirin in arterial reconstructive surgery
40. A prospective randomised study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts
41. Aspirin usage and its influence on femoro-popliteal vein graft patency
42. PTFE or HUV for femoro-popliteal bypass: A multi-centre trial
43. Platelet inhibitory therapy
44. Randomised controlled trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts
45. A prospective trial of aspirin in femoral popliteal and tibial bypass grafts
46. Effect of ticlopidine on graft patency following arterial reconstructive surgery in the lower extremity: A randomised multicentre three-year prospective study
47. Indobufen versus acetylsalicylic acid plus dipyridamole in long-term patency after femoro-popliteal bypass
48. Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: A comparative study of pentoxifylline versus acetylsalicylic acid
49. A prospective trial of sulfinpyrazone after peripheral vascular surgery
50. Prevention of post-operative thrombosis in peripheral arteriopathies
51. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration
52. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
53. Ten years of experience with aortoiliac PTFE grafts. Effects of postoperative anticoagulation on graft function and patient survival
54. Effect of antiplatelet and anticoagulant therapy on patency of fernorotibial bypass grafts
55. Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion
56. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting
57. Simultaneous therapy with antiplatelet and anticoagulant drugs in symptomatic cardiovascular disease
58. Low intensity oral anticoagulation
59. Aspirin and other platelet active drugs: The relationship between dose effectiveness and side effects
60. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
61. Indications and results with combined warfarin and antiplatelet drugs
62. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation
63. Oral anticoagulants in the secondary and primary prevention of myocardial infarction and coronary death
64. Low-dose and very low-dose warfarin
65. Suppression of hemostatis system activation by oral anticoagulants in the blood of patients with thrombotic diatheses
66. Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery
67. Prophylaxis against central vein thrombosis with low-dose warfarin
68. Double-blind randomised trial of very low-dose warfarin for prevention of thromboembolism in Stage IV breast cancer
69. Does oral anticoagulation improve patency of vein bypasses? A prospective randomised study
70. Oral anticoagulants (antithrombotic agents) for cardiovascular disorders